Lillehammer Hospital is a general hospital situated in Lillehammer, Norway. It is part of Innlandet Hospital Trust, part of the Southern and Eastern Norway Regional Health Authority. Lillehammer Heliport, Innlandet Hospital is an asphalt, ground helipad with a diameter of 18 meters.

During the past decade, Sykehuset Innlandet HF, Lillehammer conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sykehuset Innlandet HF, Lillehammer" #1 sponsor was "Norwegian University of Science and Technology" with 5 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Oslo University Hospital" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "Diakonhjemmet Hospital" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sykehuset Innlandet HF, Lillehammer" #1 collaborator was "St. Olavs Hospital" with 3 trials as a collaborator, "Sykehuset Innlandet HF" with 3 trials as a collaborator, "Haukeland University Hospital" with 2 trials as a collaborator, "South-Eastern Norway Regional Health Authority" with 2 trials as a collaborator and "University Hospital, Akershus" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Sykehuset Innlandet HF, Lillehammer" are "Atrial Fibrillation" (2 trials), "Pain" (2 trials), "Amyotrophic Lateral Sclerosis" (1 trials), "Analgesia" (1 trials) and "Anemia, Iron-Deficiency" (1 trials). Many other conditions were trialed in "Sykehuset Innlandet HF, Lillehammer" in a lesser frequency.

Most popular intervention types in "Sykehuset Innlandet HF, Lillehammer" are "Drug" (10 trials), "Procedure" (3 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflurax" (1 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sykehuset Innlandet HF, Lillehammer" are 14 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Sykehuset Innlandet HF, Lillehammer". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Sykehuset Innlandet HF, Lillehammer, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Sykehuset Innlandet HF, Lillehammer, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 5 trials that are defined as “Not Applicable".